- Home
- NAGE vs CDXS Comparison
NAGE vs CDXS Comparison
Compare NAGE & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAGE | CDXS |
|---|---|---|
| Founded | 1999 | 2002 |
| Country | United States | United States |
| Employees | 117 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.2M | 256.3M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | NAGE | CDXS |
|---|---|---|
| Price | $3.36 | $2.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | 667.9K | ★ 825.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | $16.51 | $7.73 |
| Revenue Next Year | $14.58 | $14.24 |
| P/E Ratio | $21.29 | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $3.29 | $0.96 |
| 52 Week High | $14.66 | $3.87 |
Technical Indicators
Market Signals| Indicator | NAGE | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 44.22 |
| Support Level | $3.35 | $1.57 |
| Resistance Level | $4.04 | $2.69 |
| Average True Range (ATR) | 0.15 | 0.16 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 37.74 | 26.60 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About CDXS Codexis Inc.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.